CA
AVIR icon

Clearstead Advisors’s Atea Pharmaceuticals AVIR Stock Holding History

Clearstead Advisors’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$103 Buy
+22
New +$109 ﹤0.01% 3350

Other funds holding AVIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BPC
Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
AI
Auour Investments Woburn, Massachusetts $349M AUM 13.68% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Clearstead Advisors's AVIR Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Atea Pharmaceuticals (AVIR) in Q2 2026: 22 shares worth $103. The stake represents ﹤0.01% of the portfolio and ranks #3350 among its holdings.

40 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Clearstead Advisors held 22 shares of Atea Pharmaceuticals worth $103 as of Q2 2026.
  • Atea Pharmaceuticals was a new Clearstead Advisors position in Q2 2026.
  • Atea Pharmaceuticals made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3350 holding.
  • 40 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.